Correlation between a short-term intravenous octreotide suppression test and response to antrectomy in patients with type-1 gastric neuroendocrine tumours

European Journal of Gastroenterology and Hepatology

Volumn 25, Issue 4, 2013, Pages 474-481

  Murugesan, Senthil V ^a   Steele, Islay A ^a   Dimaline, Rod ^a   Poston, Graeme J ^b   Shrotri, Milind ^b   Campbell, Fiona ^b   Varro, Andrea ^a   Pritchard, D Mark ^a  

^a UNIVERSITY OF LIVERPOOL   (United Kingdom)

^b ROYAL LIVERPOOL AND BROADGREEN UNIVERSITY HOSPITALS NHS TRUST   (United Kingdom)

Author keywords

enterochromaffin like cells; gastric carcinoid; gastrin; somatostatin; stomach

Indexed keywords

GASTRIN; HISTIDINE DECARBOXYLASE; MESSENGER RNA; OCTREOTIDE; PENTETREOTIDE IN 111; PROTON PUMP INHIBITOR;

ADULT; AGED; ARTICLE; CANCER PATIENT; CANCER SURGERY; CLINICAL ARTICLE; ENDOCRINE FUNCTION TEST; ESOPHAGOGASTRODUODENOSCOPY; FEMALE; GASTRECTOMY; GASTRIC NEUROENDOCRINE TUMOR; GASTRIN BLOOD LEVEL; GASTRITIS; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION; HUMAN; HUMAN TISSUE; HYPERGASTRINEMIA; MALE; NEUROENDOCRINE TUMOR; OCTREOTIDE SUPPRESSION TEST; PRIORITY JOURNAL; STOMACH ANTRUM RESECTION; STOMACH BIOPSY; STOMACH POLYP; STOMACH TUMOR; TREATMENT RESPONSE; TUMOR BIOPSY; TUMOR REGRESSION;

ADULT; AGED; ANTINEOPLASTIC AGENTS, HORMONAL; FEMALE; GASTRECTOMY; GASTRINS; GASTROSCOPY; HISTIDINE DECARBOXYLASE; HUMANS; INFUSIONS, INTRAVENOUS; MALE; NEUROENDOCRINE TUMORS; OCTREOTIDE; PATIENT SELECTION; PROGNOSIS; PROSPECTIVE STUDIES; PYLORIC ANTRUM; RNA, MESSENGER; STOMACH NEOPLASMS; TREATMENT OUTCOME;

EID: 84875217825     PISSN: 0954691X     EISSN: 14735687     Source Type: Journal    
DOI: 10.1097/MEG.0b013e32835cec52     Document Type: Article

References (28)

1. Burkitt MD, Pritchard DM. Review article: pathogenesis and management of gastric carcinoid tumours. Aliment Pharmacol Ther 2006; 24:1305-1320.
2. Kulke MH, Anthony LB, Bushnell DL, de Herder WW, Goldsmith SJ, Klimstra DS, et al. NANETS treatment guidelines: well-differentiated neuroendocrine tumors of the stomach and pancreas. Pancreas 2010; 39:735-752.
3. Delle Fave G, Kwekkeboom DJ, Van Cutsem E, Rindi G, Kos-Kudla B, Knigge U, et al. ENETS consensus guidelines for the management of patients with gastroduodenal neoplasms. Neuroendocrinology 2012; 95:74-87.
4. Scherubl H, Cadiot G, Jensen RT, Rosch T, Stolzel U, Kloppel G. Neuroendocrine tumors of the stomach (gastric carcinoids) are on the rise: small tumors, small problems? Endoscopy 2010; 42:664-671.
5. Hirschowitz BI, Griffith J, Pellegrin D, Cummings OW. Rapid regression of enterochromaffinlike cell gastric carcinoids in pernicious anemia after antrectomy. Gastroenterology 1992; 102:1409-1418.
6. Dakin GF, Warner RR, Pomp A, Salky B, Inabnet WB. Presentation, treatment, and outcome of type 1 gastric carcinoid tumors. J Surg Oncol 2006; 93:368-372.
7. Higham AD, Dimaline R, Varro A, Attwood S, Armstrong G, Dockray GJ, et al. Octreotide suppression test predicts beneficial outcome from antrectomy in a patient with gastric carcinoid tumor. Gastroenterology 1998; 114:817-822.
8. Fykse V, Sandvik AK, Qvigstad G, Falkmer SE, Syversen U, Waldum HL. Treatment of ECL cell carcinoids with octreotide LAR. Scand J Gastroenterol 2004; 39:621-628.
9. Campana D, Nori F, Pezzilli R, Piscitelli L, Santini D, Brocchi E, et al. Gastric endocrine tumors type I: treatment with long-acting somatostatin analogs. Endocr Relat Cancer 2008; 15:337-342.
10. Grozinsky-Glasberg S, Kaltsas G, Gur C, Gal E, Thomas D, Fichman S, et al. Long-acting somatostatin analogues are an effective treatment for type 1 gastric carcinoid tumours. Eur J Endocrinol 2008; 159:475-482.
11. Khuroo MS, Khuroo MS, Khuroo NS. Treatment of type I gastric neuroendocrine tumors with somatostatin analogs. J Gastroenterol Hepatol 2010; 25:548-554.
12. Jianu CS, Fossmark R, Syversen U, Hauso O, Fykse V, Waldum HL. Five-year follow-up of patients treated for 1 year with octreotide long-acting release for enterochromaffin-like cell carcinoids. Scand J Gastroenterol 2011; 46:456-463.
13. Fayyaz M, Mehboob S, Andersen V, Sitrin MD. Extended octreotide suppression test to determine hormone responsiveness of multiple type I gastric carcinoid tumors. Dig Dis Sci 2007; 52:1579-1585.
14. Varro A, Ardill JE. Gastrin: an analytical review. Ann Clin Biochem 2003; 40:472-480.
15. 2-terminal specific antisera. Regul Pept 1980; 1:169-186.
16. Solcia E, Bordi C, Creutzfeldt W, Dayal Y, Dayan AD, Falkmer S, et al. Histopathological classification of nonantral gastric endocrine growths in man. Digestion 1988; 41:185-200.
17. Norsett KG, Steele I, Duval C, Sammut SJ, Murugesan SV, Kenny S, et al. Gastrin stimulates expression of plasminogen activator inhibitor-1 in gastric epithelial cells. Am J Physiol Gastrointest Liver Physiol 2011; 301: G446-G453.
18. Plockinger U, Rindi G, Arnold R, Eriksson B, Krenning EP, de Herder WW, et al. Guidelines for the diagnosis and treatment of neuroendocrine gastrointestinal tumours. A consensus statement on behalf of the European Neuroendocrine Tumour Society (ENETS). Neuroendocrinology 2004; 80:394-424.
19. Ramage JK, Ahmed A, Ardill J, Bax N, Breen DJ, Caplin ME, et al. Guidelines for the management of gastroenteropancreatic neuroendocrine (including carcinoid) tumours (NETs). Gut 2012; 61:6-32.
20. Modlin IM, Lye KD, Kidd M. Carcinoid tumors of the stomach. Surg Oncol 2003; 12:153-172.
21. Borch K, Ahren B, Ahlman H, Falkmer S, Granerus G, Grimelius L. Gastric carcinoids: biologic behavior and prognosis after differentiated treatment in relation to type. Ann Surg 2005; 242:64-73.
22. Ichikawa J, Tanabe S, Koizumi W, Kida Y, Imaizumi H, Kida M, et al. Endoscopic mucosal resection in the management of gastric carcinoid tumors. Endoscopy 2003; 35:203-206.
23. Hopper AD, Bourke MJ, Hourigan LF, Tran K, Moss A, Swan MP. En-bloc resection of multiple type 1 gastric carcinoid tumors by endoscopic multiband mucosectomy. J Gastroenterol Hepatol 2009; 24:1516-1521.
24. Higashino K, Iishi H, Narahara H, Uedo N, Yano H, Ishiguro S, et al. Endoscopic resection with a two-channel videoendoscope for gastric carcinoid tumors. Hepatogastroenterology 2004; 51:269-272.
25. Richards AT, Hinder RA, Harrison AC. Gastric carcinoid tumours associated with hypergastrinaemia and pernicious anaemia-regression of tumors by antrectomy. A case report. S Afr Med J 1987; 72:51-53.
26. Eckhauser FE, Lloyd RV, Thompson NW, Raper SE, Vinik AI. Antrectomy for multicentric, argyrophil gastric carcinoids: a preliminary report. Surgery 1988; 104:1046-1053.
27. Hoshino M, Omura N, Yano F, Tsuboi K, Matsumoto A, Yamamoto SR, et al. Usefulness of laparoscope-assisted antrectomy for gastric carcinoids with hypergastrinemia. Hepatogastroenterology 2010; 57:379-382.
28. Ozao-Choy J, Buch K, Strauchen JA, Warner RR, Divino CM. Laparoscopic antrectomy for the treatment of type I gastric carcinoid tumors. J Surg Res 2010; 162:22-25.